查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
非酒精性脂肪性肝炎治疗市场规模、份额和趋势分析报告：按药物类型、最终用户、地区、分部预测2022-2030
市场调查报告书
商品编码
1122252

非酒精性脂肪性肝炎治疗市场规模、份额和趋势分析报告：按药物类型、最终用户、地区、分部预测2022-2030

Non-Alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug Type (Obeticholic Acid, Lanifibranor, Semaglutide, Resmetirom, Aramchol, Cenicriviroc), By End-use, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

非酒精性脂肪性肝炎治疗市场增长和趋势

Grandview Research 的最新报告显示，到 2030 年，全球非酒精性脂肪性肝炎治疗市场预计将达到 159.5 亿美元。从 2022 年到 2030 年，预计将以 39.2% 的复合年增长率增长。非酒精性脂肪性肝炎 (NASH) 治疗市场的主要动力是诺和诺德的 Ozempic、Intercept 的 Ocaliva 和 Inventiva 的 Ranifibranol 等药物的推出。

由于无法获得批准的药物、高疾病负担和復杂的诊断程序等因素，NASH 治疗市场存在大量未满足的需求。市场目前以□格列酮和维生素 E 等标籤外药物为主。这些是全球该领域最广泛使用的处方药。然而，为了解决未得到满足的机会，市场参与者正在大力投资研发活动，以开发治疗 NASH 的新疗法。目前有超过 50 个候选管道。

计划在预测期内推出的后期管道候选药物包括来自 Inventiva Pharma 的 Lanifibranor、来自 Intercept Pharmaceuticals 的 Oveticholic acid、来自 Galmed Pharmaceuticals Ltd. 的 Aramchol、来自 Novo Nordisk A/S 的 Semaglutide 和 Madrigal Pharmaceuticals, Inc.，包括 Resmeirom 等。其中，Intercept 的奥贝胆酸 (OCA) 和 Madrigal 的 resmethirom 是最热门的药物，与其他管道候选药物相比，预计将较早进入。

研究表明，非酒精性脂肪性肝炎与肥胖和糖尿病密切相关。研究发现，大约 80% 的 NASH 患者肥胖。在美国和其他地方，CDC 2021 年的最新统计数据显示，肥胖率高达 42%。我们也知道，美国、日本等国家是世界上非酒精性脂肪性肝炎患病率最高的国家，而这些国家的肥胖和糖尿病负担也很重。所有这些因素将在整个预测期内推动 NASH 治疗市场。

主要製药公司的战略举措和快速通道指定等监管支持政策预计将进一步加速市场增长。2022 年 5 月，辉瑞 (Pfizer) 的肘部胃司他/cresacostat 组合获得了快速通道指定。它是治疗非酒精性脂肪性肝炎的潜在药物组合之一。这种药物名称有助于药物的临床试验过程。

肝活检是诊断非酒精性脂肪性肝炎的金标准。由于这种诊断测试的侵入性，它仅用于有症状的病例，导致全球平均 NASH 诊断率约为 20%。市场增长预计将受到非侵入性基于生物标誌物的非酒精性脂肪性肝炎诊断测试的阻碍。

非酒精性脂肪性肝炎治疗市场报告亮点

维生素 E 和□格列酮（标籤外）是唯一的贡献者，2021 年市场份额为 100%。这可能是由于没有市场批准的药物

2021年，零售和专业药房占63.8%的份额。零售和专业药房非常适合 NASH 等慢性病，患者通常与家庭护理环境有关

北美主导了 NASH 疗法的收入。这可以归因于疾病意识的提高、更好的医疗保健设施以及比其他地区相对更高的治疗率。

目录

第一章 调查方法和范围

  • 市场细分和范围
    • 段范围
    • 区域范围
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 第一次调查的内容
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法：产品流方法
  • 调查假设
  • 二级信息列表
  • 缩略语表
  • 目的

第二章执行摘要

  • 市场概况

3. 非酒精性脂肪性肝炎治疗市场变量、趋势和范围

  • 绘製渗透率和增长前景
  • 监管状况
  • 行业分析——波特五力
  • PESTEL 分析（政法、经济学、技术）
  • 流行病学分析
  • 未满足需求分析
  • 按阶段进行管道分析

4 非酒精性脂肪性肝炎治疗市场：细分分析，按药物类型，2018-2030 年（百万美元）

  • 非酒精性脂肪性肝炎治疗市场：药物种类波动分析
  • 维生素E和□格列酮
  • 奥贝胆酸 (OCA)
  • 雷尼布诺
  • 索马鲁□
  • 瑞斯美隆
  • 阿拉姆科尔
  • 塞尼克里维岩
  • 其他

5 非酒精性脂肪性肝炎治疗市场：细分分析，按最终用途，2018-2030 年（百万美元）

  • 非酒精性脂肪性肝炎治疗市场：最终用途变化分析
  • 医院药房
  • 零售和专业药店
  • 其他

6. 非酒精性脂肪性肝炎治疗市场：细分分析，按地区，2018-2030 年（百万美元）

  • 定义和范围
  • 2021 年和 2030 年区域市场份额分析
  • 区域市场快照
  • 2021-2030 年市场规模、预测、收入、趋势分析
    • 北美
      • 美国
      • 加拿大
    • 欧洲
      • 英国
      • 德国
      • 西班牙
      • 法国
      • 意大利
    • 亚太地区
      • 日本
      • 中国
      • 印度
      • 韩国
      • 澳大利亚
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 多边环境协定
      • 南非
      • 沙特阿拉伯
      • 阿拉伯联合酋长国

7. 非酒精性脂肪性肝炎治疗市场：竞争分析

  • 主要市场参与者的最新发展和影响分析
    • 新产品发布
    • 併购
    • 伙伴关係和战略合作
  • 公司分类
    • 创新者
    • 市场领导者
  • 供应商情况
    • 主要经销商及渠道合作伙伴名单
  • 主要客户
  • 2021 年主要参与者的市场份额分析
  • 上市公司
    • 公司市场分析
    • 竞争仪錶盘分析
      • 市场差异化因素
  • 民营企业
    • 主要初创企业名单
    • 区域网络图
  • 公司简介
    • Intercept Pharmaceuticals
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Galmed Pharmaceuticals
      • 公司简介
      • 财务绩效
      • 产品基准
    • Inventiva Pharma
      • 公司简介
      • 财务绩效
      • 产品基准
    • Novo Nordisk A/S
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • AbbVie Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Galectin Therapeutics Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Madrigal Pharmaceuticals
      • 公司简介
      • 产品基准
    • NGM Biopharmaceuticals Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Bristol Myers Squibb
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Novo Nordisk A/S
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Gilead Sciences Inc
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
Product Code: GVR-4-68039-964-6

Non-Alcoholic Steatohepatitis Treatment Market Growth & Trends:

The global non-alcoholic steatohepatitis treatment market size is expected to reach USD 15.95 billion by 2030, according to a new report by Grand View Research, Inc. The industry is projected to expand at a CAGR of 39.2% from 2022 to 2030. The non-alcoholic steatohepatitis (NASH) treatment market is primarily driven by the launch of drugs such as Novo Nordisk's Ozempic, Intercept's Ocaliva, and Inventiva's lanifibranor, among others.

The NASH treatment market has major unmet needs owing to factors such as the unavailability of approved drugs, high disease burden, and complex diagnostic procedures. Currently, the market is dominated by off-label drugs such as Pioglitazone and Vitamin E. These are widely prescribed drugs in this space globally. However, to address the unmet opportunity, key market players are heavily investing in R&D activities to develop novel therapeutics for NASH treatment. Currently, there are more than 50 pipeline candidates.

Some of the late-stage pipeline candidates expected to launch during the forecast period include Inventiva Pharma's Lanifibranor, Intercept Pharmaceuticals' Obeticholic acid, Galmed Pharmaceuticals Ltd.'s Aramchol, Novo Nordisk A/S's Semaglutide, and Madrigal Pharmaceuticals, Inc.'s Resmetirom. Among these, Intercept Pharmaceuticals's Obeticholic Acid (OCA), and Madrigal Pharmaceuticals, Inc.'s Resmetirom, are the most looked upon drugs and are expected to enter comparatively earlier than other pipeline candidates.

Research studies reveal that non-alcoholic steatohepatitis is strongly associated with obesity and diabetes. Research studies show that around 80% of NASH patients are obese. In countries such as the U.S., the obesity prevalence is as high as 42%, according to the latest 2021 statistics by CDC. In addition, countries such as the U.S. and Japan account for the highest prevalence of non-alcoholic steatohepatitis globally, and these countries also have a high burden of obesity and diabetes. All such factors will fuel the NASH treatment market throughout the forecast period.

Strategic initiatives by pharma giants and supportive regulatory authority policies such as fast track designation are further expected to accelerate the market growth. In May 2022, Pfizer, Inc.'s Ervogastat/Clesacostat Combination therapy received fast track designation. This is one of the potential drug combinations for the treatment of non-alcoholic steatohepatitis. Such drug designation boosts the clinical trial process for drugs.

Liver biopsy is the gold standard for the diagnosis of non-alcoholic steatohepatitis. The invasive nature of this diagnostics test limits its usage to only symptomatic cases, and as a result, the global average diagnostic rate for NASH is around 20%. The unavailability of biomarkers-based non-invasive tests for the diagnosis of non-alcoholic steatohepatitis is expected to impede the market growth.

Non-Alcoholic Steatohepatitis Treatment Market Report Highlights:

  • Vitamin E and Pioglitazone (Off-label) acted as the lone contributor with 100% share to the market in 2021. This can be attributed to the unavailability of approved drugs in the market
  • The retail and specialty pharmacies segment held a share of 63.8% in 2021. Retail and specialty pharmacies are more compatible with chronic diseases such as NASH, where the patients are more commonly associated with homecare settings
  • North America dominated the overall NASH treatment space in terms of revenue. This can be attributed to increased disease awareness, better healthcare facilities, and comparatively higher treatment rate than in other regions

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Non-Alcoholic steatohepatitis treatment market Variables, Trends, and Scope

  • 3.1 Penetration and Growth Prospect Mapping
  • 3.2 Regulatory Landscape
  • 3.3 Industry Analysis - Porter's Five Forces
  • 3.4 PESTEL Analysis (Political & Legal, Economic, and Technological)
  • 3.5 Epidemiology Analysis
  • 3.6 Unmet need analysis
  • 3.7 Pipeline Analysis, by Phase

Chapter 4 Non-Alcoholic steatohepatitis treatment market: Segment Analysis, by Drug Type, 2018 - 2030 (USD Million)

  • 4.1 Non-Alcoholic steatohepatitis treatment market: Drug Type Movement Analysis
  • 4.2 Vitamin E and Pioglitazone
    • 4.2.1 Vitamin E and Pioglitazone Market, 2018 - 2030 (USD Million)
  • 4.3 Obeticholic Acid (OCA)
    • 4.3.1 Obeticholic Acid (OCA) market, 2018 - 2030 (USD Million)
  • 4.4 Lanifibranor
    • 4.4.1 Lanifibranor Market, 2018 - 2030 (USD Million)
  • 4.5 Semaglutide
    • 4.5.1 Semaglutide Market, 2018 - 2030 (USD Million)
  • 4.6 Resmetirom
    • 4.6.1 Resmetirom Market, 2018 - 2030 (USD Million)
  • 4.7 Aramchol
    • 4.7.1 Aramchol Market, 2018 - 2030 (USD Million)
  • 4.8 Cenicriviroc
    • 4.8.1 Cenicriviroc Market, 2018 - 2030 (USD Million)
  • 4.9 Others
    • 4.9.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Non-Alcoholic steatohepatitis treatment market: Segment Analysis, by End-use, 2018 - 2030 (USD Million)

  • 5.1 Non-Alcoholic steatohepatitis treatment market: End-use Movement Analysis
  • 5.2 Hospital Pharmacies
    • 5.2.1 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.3 Retail and Specialty Pharmacies
    • 5.3.1 Retail and Specialty Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.4 Others
    • 5.4.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Non-Alcoholic steatohepatitis treatment market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 6.1 Definition & Scope
  • 6.2 Regional Market Share Analysis, 2021 & 2030
  • 6.3 Regional Market Snapshot
  • 6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
    • 6.4.1 North America
      • 6.4.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 6.4.1.2 U.S.
      • 6.4.1.2.1 U.S. Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.1.3 Canada
      • 6.4.1.3.1 Canada Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
    • 6.4.2 Europe
      • 6.4.2.1 Europe Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.2.2 UK
      • 6.4.2.2.1 UK Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.2.3 Germany
      • 6.4.2.3.1 Germany Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.2.4 Spain
      • 6.4.2.4.1 Spain Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.2.5 France
      • 6.4.2.5.1 France Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.2.6 Italy
      • 6.4.2.6.1 Italy Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
    • 6.4.3 Asia Pacific
      • 6.4.3.1 Asia Pacific Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.3.2 Japan
      • 6.4.3.2.1 Japan Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.3.3 China
      • 6.4.3.3.1 China Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.3.4 India
      • 6.4.3.4.1 India Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.3.5 South Korea
      • 6.4.3.5.1 South Korea Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.3.6 Australia
      • 6.4.3.6.1 Australia Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
    • 6.4.4 Latin America
      • 6.4.4.1 Latin America Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.4.2 Brazil
      • 6.4.4.2.1 Brazil Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.4.3 Mexico
      • 6.4.4.3.1 Mexico Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.4.4 Argentina
      • 6.4.4.4.1 Argentina Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
    • 6.4.5 MEA
      • 6.4.5.1 MEA Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.5.2 South Africa
      • 6.4.5.2.1 South Africa Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.5.3 Saudi Arabia
      • 6.4.5.3.1 Saudi Arabia Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.5.4 UAE
      • 6.4.5.4.1 UAE Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

Chapter 7 Non-Alcoholic steatohepatitis treatment market: Competitive Analysis

  • 7.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 7.1.1 New Product Launches
    • 7.1.2 Mergers and Acquisitions
    • 7.1.3 Partnerships and Strategic Collaboration
  • 7.2 Company Categorization
    • 7.2.1 Innovators
    • 7.2.2 Market Leaders
  • 7.3 Vendor Landscape
    • 7.3.1 List of key distributors and channel partners
  • 7.4 Key Customers
  • 7.5 Key Company Market Share Analysis, 2021
  • 7.6 Public Companies
    • 7.6.1 Company market position analysis
    • 7.6.2 Competitive Dashboard Analysis
      • 7.6.1.1 Market Differentiators
  • 7.7 Private Companies
    • 7.7.1 List of key emerging companies
    • 7.7.2 Regional Network Map
  • 7.8 Company Profiles
    • 7.8.1 Intercept Pharmaceuticals
      • 7.8.1.1 Company overview
      • 7.8.1.2 Financial performance
      • 7.8.1.3 Product benchmarking
      • 7.8.1.4 Strategic initiatives
    • 7.8.2 Galmed Pharmaceuticals
      • 7.8.2.1 Company overview
      • 7.8.2.2 Financial performance
      • 7.8.2.3 Product benchmarking
    • 7.8.3 Inventiva Pharma
      • 7.8.3.1 Company overview
      • 7.8.3.2 Financial performance
      • 7.8.3.3 Product benchmarking
    • 7.8.4 Novo Nordisk A/S
      • 7.8.4.1 Company overview
      • 7.8.4.2 Financial Performance
      • 7.8.4.3 Product Benchmarking
      • 7.8.4.4 Strategic initiatives
    • 7.8.5 AbbVie Inc.
      • 7.8.5.1 Company overview
      • 7.8.5.3 Financial Performance
      • 7.8.5.4 Product benchmarking
      • 7.8.5.5 Strategic initiatives
    • 7.8.6 Galectin Therapeutics Inc.
      • 7.8.6.1 Company overview
      • 7.8.6.2 Financial performance
      • 7.8.6.3 Product benchmarking
      • 7.8.6.4 Strategic initiatives
    • 7.8.7 Madrigal Pharmaceuticals
      • 7.8.7.1 Company overview
      • 7.8.7.2 Product benchmarking
    • 7.8.8 NGM Biopharmaceuticals Inc.
      • 7.8.8.1 Company overview
      • 7.8.8.2 Financial performance
      • 7.8.8.3 Product benchmarking
      • 7.8.8.4 Strategic initiatives
    • 7.8.9 Bristol Myers Squibb
      • 7.8.9.1 Company overview
      • 7.8.9.2 Financial performance
      • 7.8.9.3 Product benchmarking
      • 7.8.9.4 Strategic initiatives
    • 7.8.10 Novo Nordisk A/S
      • 7.8.10.1 Company overview
      • 7.8.10.2 Financial performance
      • 7.8.10.3 Product benchmarking
      • 7.8.10.4 Strategic initiatives
    • 7.8.11 Gilead Sciences Inc
      • 7.8.11.1 Company overview
      • 7.8.11.2 Financial performance
      • 7.8.11.3 Product benchmarking
      • 7.8.11.4 Strategic initiatives 

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Incidence of Diseases
  • Table 4 Global Non-Alcoholic steatohepatitis treatment market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 6 Global Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 7 North America Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 9 North America Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 10 U.S. Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 12 Canada Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 13 Canada Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 14 Europe Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 16 Europe Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 17 Germany Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 18 Germany Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 19 UK Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 20 UK Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 21 France Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 22 France Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 23 Italy Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 24 Italy Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 25 Spain Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 26 Spain Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 27 Asia Pacific Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 29 Asia pacific Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 30 Japan Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 31 Japan Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 32 China Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 33 China Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 34 India Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 35 India Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 36 South Korea Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 37 South Korea Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 38 Australia Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 39 Australia Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 40 Latin America Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 41 Latin America Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 42 Latin America Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 43 Brazil Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 44 Brazil Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 45 Mexico Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 46 Mexico Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 47 Argentina Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 48 Argentina Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 49 Middle East & Africa Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Middle East & Africa Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 51 Middle East & Africa Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 52 Saudi Arabia Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 54 South Africa Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 55 South Africa Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 56 UAE Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 57 UAE Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Non-Alcoholic steatohepatitis treatment market Segmentation
  • FIG. 2 Market research process
  • FIG. 3 Data triangulation techniques
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value-chain-based sizing & forecasting
  • FIG. 7 QFD modeling for market share assessment
  • FIG. 8 Market formulation & validation
  • FIG. 9 Non-alcoholic steatohepatitis treatment market snapshot
  • FIG. 10 Parent market outlook
  • FIG. 11 Related/ancillary market outlook, revenue, 2021 (USD Million)
  • FIG. 12 Penetration and growth prospect mapping
  • FIG. 13 Non-alcoholic steatohepatitis treatment market driver impact
  • FIG. 14 Non-alcoholic steatohepatitis treatment market restraint impact
  • FIG. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • FIG. 16 Industry Analysis - Porter's Five Forces
  • FIG. 17 Strategy mapping
  • FIG. 18 Non- alcoholic steatohepatitis treatment market: Drug type outlook and key takeaways
  • FIG. 19 Non- alcoholic steatohepatitis treatment market: Drug type movement analysis & market share 2021 & 2030
  • FIG. 20 Vitamin E and Pioglitazone non-alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 21 Obeticholic Acid non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 22 Lanifibranor non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 23 Semaglutide non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 24 Resmetirom non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 25 Aramchol non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 26 Cenicriviroc non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 27 Others non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 28 Non- alcoholic steatohepatitis treatment market: End-use outlook and key takeaways
  • FIG. 29 Non- alcoholic steatohepatitis treatment market: End-use movement analysis & market share 2021 & 2030
  • FIG. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 31 Retail and speciality pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 33 Non-alcoholic steatohepatitis treatment market: Regional outlook and key takeaways
  • FIG. 34 Regional outlook, 2021 & 2030
  • FIG. 35 North America
  • FIG. 36 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 37 U.S.
  • FIG. 38 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 39 Canada
  • FIG. 40 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 41 Europe
  • FIG. 42 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 43 UK
  • FIG. 44 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 45 Germany
  • FIG. 46 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 47 France
  • FIG. 48 France market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 49 Italy
  • FIG. 50 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 51 Spain
  • FIG. 52 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 53 Asia-Pacific
  • FIG. 54 Asia-Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 55 Japan
  • FIG. 56 Japan market estimates and forecast, 2018 - 2030(USD Million)
  • FIG. 57 China
  • FIG. 58 China market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 59 India
  • FIG. 60 India market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 61 South Korea
  • FIG. 62 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 63 Australia
  • FIG. 64 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 65 Latin America
  • FIG. 66 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 67 Brazil
  • FIG. 68 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 69 Mexico
  • FIG. 70 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 71 Argentina
  • FIG. 72 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 73 Middle East & Africa
  • FIG. 74 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 75 South Africa
  • FIG. 76 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 77 Saudi Arabia
  • FIG. 78 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 79 UAE
  • FIG. 80 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 81 Market differentiators
  • FIG. 82 Key company market share analysis, 2021
  • FIG. 83 Company market position analysis
  • FIG. 84 Competitive dashboard analysis
  • FIG. 85 Regional network map